Vir Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. on February 16, 2023, reporting events occurring on February 13, 2023. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the departure of the incumbent.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change is the leadership transition in the finance function:
- New Appointment: Sung Lee appointed as Executive Vice President and Chief Financial Officer, effective March 27, 2023.
- Departure: Howard Horn will step down as CFO on the effective date but will remain as Executive Vice President until April 28, 2023, to assist with the transition.
Compensation, Outlook, and Risks
Management commentary is limited to the details of Mr. Lee's employment agreement. No financial guidance or operational outlook is provided in this filing. Key compensation terms include:
- Base Salary: $525,000 annualized.
- Target Bonus: 45% of annualized base salary.
- Sign-on Bonus: One-time cash payment of $500,000, payable on the one-year anniversary of the effective date, contingent on continued employment.
- Relocation Expenses: Up to approximately $460,000 for relocation from Germany to San Francisco. Full reimbursement is required if employment terminates for Cause or without Good Reason within one year.
- Equity Awards:
- Option to purchase 133,000 shares of common stock (vesting over 4 years).
- Restricted Stock Units (RSUs) for 66,500 shares (vesting over 4 years).
- Severance Benefits: Under the Change in Control and Severance Benefit Plan, Mr. Lee is eligible for 12 months of base salary plus target bonus and full equity acceleration in the event of a covered termination within 12 months of a change in control. Outside this period, coverage is 9 months of base salary plus pro-rated bonus.
Investor Verification Checklist
- Verify the exact effective date of the CFO transition (March 27, 2023) and the interim role of the outgoing CFO.
- Confirm the vesting schedules and exercise price for the 133,000 stock options and 66,500 RSUs granted to Mr. Lee.
- Review the specific definitions of "Cause" and "Good Reason" in the Severance Plan to understand the conditions for the $460,000 relocation expense reimbursement.
- Monitor future filings for the impact of the $500,000 sign-on bonus and relocation costs on the company's cash flow and stock-based compensation expenses.